Comparative Pharmacology
Head-to-head clinical analysis: ASACOL HD versus AZULFIDINE EN TABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL HD versus AZULFIDINE EN TABS.
ASACOL HD vs AZULFIDINE EN-TABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) derivative that acts locally in the colon to reduce inflammation by inhibiting prostaglandin production and leukotriene synthesis, likely through scavenging free radicals and blocking cytokine release.
Sulfasalazine is a prodrug that is cleaved by colonic bacteria to 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis. It also scavenges reactive oxygen species and inhibits NF-κB activation, leading to anti-inflammatory effects.
2 tablets (1600 mg) once daily with or without food.
500 mg orally twice daily, titrated to 1 g twice daily after 2 weeks for rheumatoid arthritis; 2 g daily in divided doses for ulcerative colitis.
None Documented
None Documented
Terminal elimination half-life is 5-10 hours for 5-ASA and 5-10 hours for acetyl-5-ASA; clinically, it supports twice-daily dosing.
Sulfapyridine: 12-15 hours (clinical context: dosing interval typically 6-12 hours due to sulfapyridine accumulation; mesalamine: 0.6-1.5 hours, not clinically relevant)
Primarily renal excretion of acetyl-5-ASA (about 80% of absorbed dose) and unchanged 5-ASA; minor fecal elimination (<20%).
Renal (50% as sulfapyridine metabolites, 33% as acetylsulfapyridine, 15% as sulfapyridine glucuronide, 2% as unchanged sulfapyridine; 15-20% as mesalamine metabolites), biliary/fecal (minimal, primarily mesalamine excreted in feces)
Category C
Category C
Aminosalicylate
Aminosalicylate